Fed. Circ. Casts Doubt On Novartis MS Drug PTAB Win
A Federal Circuit panel appeared skeptical Thursday of Novartis' argument that the written description of a patent covering multiple sclerosis drug Gilenya doesn't need to explicitly say the treatment excludes a...To view the full article, register now.
Already a subscriber? Click here to view full article